Enliven Therapeutics News

Enliven Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Jun 20 14:47 ET

Enliven Therapeutics | 8-K: Current report

Jun 18 17:14 ET

Enliven Therapeutics | 8-K/A: Current report (Amendment)

May 29 16:11 ET

Enliven Therapeutics | DEFA14A: Others

Apr 26 22:29 ET

Enliven Therapeutics | DEF 14A: Definitive information statements

Apr 26 16:10 ET

Enliven Therapeutics | S-3: Registration statement for specified transactions by certain issuers

Apr 18 16:47 ET

Enliven Therapeutics | PRE 14A: Preliminary proxy statements relating to merger or acquisition

Apr 15 16:11 ET

Enliven Therapeutics | 8-K: Current report

Apr 11 08:04 ET

Enliven Therapeutics | 8-K: Current report

Apr 9 16:16 ET

Enliven Therapeutics | 8-K: Current report

Mar 19 08:51 ET

Enliven Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Mar 14 17:20 ET

Enliven Therapeutics | 8-K: Current report

Jun 23, 2023 18:18 ET

Enliven Therapeutics | S-3: Registration statement for specified transactions by certain issuers

Jun 23, 2023 17:28 ET

Enliven Therapeutics | 8-K: Current report

Jun 23, 2023 16:03 ET

Enliven Therapeutics | DEFA14A: Others

Apr 28, 2023 16:11 ET

Enliven Therapeutics | DEF 14A: Definitive proxy statements

Apr 28, 2023 16:08 ET

Enliven Therapeutics | 8-K/A: Current report (Amendment)

Mar 21, 2023 16:06 ET

Enliven Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Mar 1, 2023 16:56 ET

Enliven Therapeutics | 8-K: Current report

Mar 1, 2023 16:06 ET

IMARA | 8-K: Current report

Feb 22, 2023 16:45 ET